Literature DB >> 15860657

Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes.

Sharon E Murphy1, Vytautas Raulinaitis, Kathryn M Brown.   

Abstract

In smokers, the primary pathway of nicotine metabolism is P450 2A6-catalyzed 5'-oxidation. The nicotine Delta(5'(1'))-iminium ion product of this reaction is further metabolized to cotinine by aldehyde oxidase. Previous investigators have reported kinetic parameters for cotinine formation using human liver cytosol as a source of aldehyde oxidase. Using [5-(3)H]nicotine and radioflow high-performance liquid chromatography analysis, we determined kinetic parameters for nicotine 5'-oxidation by P450 2A6 and the closely related human extrahepatic P450 2A13 as well as the rodent P450s 2A3, 2A4, and 2A5. The formation of both cotinine and nicotine Delta(5'(1'))-iminium ion was monitored. The K(m) and V(max) values for P450 2A6 were 144 +/- 15 muM and 1.30 +/- 0.05 pmol/min/pmol, respectively. Previously reported K(m) values for cotinine formation by P450 2A6 in the presence of cytosol were much lower, ranging from 11 to 45 muM. P450 2A13 was a somewhat better catalyst of nicotine Delta(5'(1'))-iminium formation, with 2-fold lower K(m) and 2-fold higher V(max) values than P450 2A6. The rat P450 2A3 and the mouse P450 2A5, which are 85 and 84% identical to P450 2A6, were much more efficient catalysts of nicotine 5'-oxidation. P450 2A4 was not an efficient catalyst of nicotine metabolism. Whereas 5'-oxidation was the major pathway of nicotine metabolism for all five P450 2A enzymes, these enzymes also catalyzed methyl oxidation. Nornicotine, the product of this reaction was detected as 5 to 15% of the total nicotine metabolites. Nornicotine is the amine precursor to the esophageal carcinogen N'-nitrosonornicotine. Therefore, methyl oxidation of nicotine by P450 2A6 or P450 2A13 followed by nitrosation of nornicotine are possible endogenous pathways of N'-nitrosonornicotine formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860657     DOI: 10.1124/dmd.105.004549

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  28 in total

1.  Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice.

Authors:  Deniz Bagdas; Pretal P Muldoon; Andy Z X Zhu; Rachel F Tyndale; M Imad Damaj
Journal:  Neuropharmacology       Date:  2014-05-21       Impact factor: 5.250

2.  Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Authors:  Timothy W Lefever; Youn O K Lee; Alexander L Kovach; Melanie A R Silinski; Julie A Marusich; Brian F Thomas; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2017-01-18       Impact factor: 4.492

3.  Structural and biophysical characterization of human cytochromes P450 2B6 and 2A6 bound to volatile hydrocarbons: analysis and comparison.

Authors:  Manish B Shah; P Ross Wilderman; Jingbao Liu; Hyun-Hee Jang; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Mol Pharmacol       Date:  2015-01-13       Impact factor: 4.436

4.  Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.

Authors:  Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2016-11-22       Impact factor: 3.739

5.  Fundamental reaction pathways for cytochrome P450-catalyzed 5'-hydroxylation and N-demethylation of nicotine.

Authors:  Dongmei Li; Yong Wang; Keli Han; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-07-15       Impact factor: 2.991

6.  Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes.

Authors:  Natasha M DeVore; Emily E Scott
Journal:  J Biol Chem       Date:  2012-06-14       Impact factor: 5.157

7.  Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.

Authors:  Jeannette Zinggeler Berg; Jesse Mason; Angela J Boettcher; Dorothy K Hatsukami; Sharon E Murphy
Journal:  J Pharmacol Exp Ther       Date:  2009-09-28       Impact factor: 4.030

Review 8.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

9.  Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model.

Authors:  Xin Zhou; Xiaoliang Zhuo; Fang Xie; Kerri Kluetzman; Yue-Zhong Shu; W Griffith Humphreys; Xinxin Ding
Journal:  J Pharmacol Exp Ther       Date:  2009-11-18       Impact factor: 4.030

10.  Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5.

Authors:  Eric C K Siu; Dieter B Wildenauer; Rachel F Tyndale
Journal:  Psychopharmacology (Berl)       Date:  2006-01-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.